This inventor holds 2 USPTO granted patents. Top assignees: Apogee Therapeutics, Inc., Paragon Therapeutics, Inc.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Innovations by Tomas Kiselak in Antibody Development
Introduction
Tomas Kiselak is an accomplished inventor based in Waltham, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target interleukin 13 (IL-13). His work is crucial for advancing treatments for inflammatory diseases.
Latest Patents
Tomas Kiselak holds a patent for "Antibodies that bind interleukin 13 and methods of use." This patent describes novel and improved antibodies that bind IL-13 and outlines methods for inhibiting its biological activity. The patent also details pharmaceutical compositions that include these anti-IL-13 antibodies, which are intended for the treatment of inflammatory diseases associated with elevated levels of IL-13 and/or IgE.
Career Highlights
Kiselak is currently associated with Apogee Therapeutics, Inc., where he continues to innovate in the field of therapeutic antibodies. His work has the potential to impact the treatment landscape for various inflammatory conditions.
Collaborations
Throughout his career, Tomas has collaborated with notable professionals in the field, including Hussam H Shaheen and Kenneth Evan Thompson. These collaborations have further enriched his research and development efforts.
Conclusion
Tomas Kiselak's contributions to antibody development represent a significant advancement in biotechnology. His innovative work continues to pave the way for new therapeutic options in treating inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile